Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma

Annals of Oncology

Volumn 21, Issue 1, 2009, Pages 126-132

  Avigdor, A ^a,b   Bulvik, S ^c   Levi, I ^d   Dann, E J ^e   Shemtov, N ^a   Perez Avraham, G ^d   Shimoni, A ^a   Nagler, A ^a   Ben Bassat, I ^a   Polliack, A ^f  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c LANIADO HOSPITAL   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^e RAMBAM MEDICAL CENTER   (Israel)

^f HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Chemotherapy; Hodgkin's lymphoma; PET CT scan

Indexed keywords

BLEOMYCIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ADVANCED CANCER; ARTICLE; AVASCULAR NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; FEMALE; FEMUR HEAD NECROSIS; HEMATOLOGIC DISEASE; HODGKIN DISEASE; HUMAN; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 77949332459     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp271     Document Type: Article

References (26)

1. Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 2002; 346: 1417-1418.
2. Duggan DB, Petroni GR, Johnson JL et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003; 21: 607-614.
3. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506-1514.
4. Van der Kaaij MA, Heutte N, Le SN et al. Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007; 25: 2825-2832.
5. Diehl V. Advanced Hodgkin's disease: ABVD is better, yet is not good enough!. J Clin Oncol 2003; 21: 583-585.
6. Diehl V, Franklin J, Pfreundschuh M et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-2395.
7. Sieber M, Bredenfeld H, Josting A et al. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 1734-1739.
8. Horning SJ, Hoppe RT, Breslin S et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002; 20: 630-637.
9. Radford JA, Rohatiner AZ, Ryder WD et al. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol 2002; 20: 2988-2994.
10. Engert A, Franklin J, Diehl V. Long-term follow-up of BEACOPP escalated chemotherapy in patients with advanced-stage Hodgkin lymphoma on behalf of the German Hodgkin Study Group. Blood (ASH Annual Meeting Abstracts) 2007; 110: (Abstr 211).
11. Sieniawski M, Reineke T, Nogova L et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008; 111: 71-76.
12. Behringer K, Breuer K, Reineke T et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005; 23: 7555-7564.
13. Behringer K, Diehl V. Twenty-five years clinical trials of the German Hodgkin Study Group (GHSG). Eur J Haematol Suppl 2005; 75: 21-25.
14. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253.
15. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
16. Federico M, Luminari S, Iannitto E et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009; 27: 805-811.
17. Ballova V, Ruffer JU, Haverkamp H et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 2005; 16: 124-131.
18. Engert A, Ballova V, Haverkamp H et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 2005; 23: 5052-5060.
19. Gallamini A, Rigacci L, Merli F et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006; 91: 475-481.
20. Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F]fluoro-2-deoxy-Dglucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-3752.
21. Hutchings M, Mikhaeel NG, Fields PA et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005; 16: 1160-1168.
22. Hutchings M, Loft A, Hansen M et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52-59.
23. Zinzani PL, Tani M, Fanti S et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol 2006; 17: 1296-1300.
24. Gallamini A, Viviaru S, Bonfante V et al. Early interim FDG-PET during intensified BEACOPP therapy for advanced stage Hodgkin disease shows a lower predictive value than during ABVD. Haematologica 2007; 92: 143-144.
25. Kobe C, Dietlein M, Franklin J et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008; 112: 3989-3994.
26. Dann EJ, Bar-Shalom R, Tamir A et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007; 109: 905-909.